Century Therapeutics
Century Therapeutics' revenue rose 1556.8% to $109 million in fiscal 2025. Its operating margin was −15.8%, up from −2,096.5% a year earlier. Free cash flow was −$105 million. The diluted share count rose 10.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Century Therapeutics does
Century Therapeutics is a biotechnology company developing cell therapies for autoimmune diseases, including type 1 diabetes, and for cancer. Its therapies are allogeneic, meaning they are made from healthy donor cells for use in any patient, rather than from each patient's own cells. It starts from induced pluripotent stem cells, which can renew themselves and turn into almost any cell type. It uses gene editing to change them, and says its technology is intended to keep a patient's immune system from rejecting the cells.
It has no products approved for sale and has never earned revenue from product sales. Its programs include insulin-producing beta islet cells and immune cells, namely T cells and natural killer cells. CNTY-101 is a CD19-targeted natural killer cell therapy being tested in B-cell-mediated autoimmune diseases, and CNTY-308 is a CD19-targeted T cell therapy candidate.
The company says it has built its own manufacturing capabilities for these cells. All its candidates are still in development.
Its biggest risks, as it describes them
- It has lost money since it began, has never sold a product and may never be profitable.
- It needs more funding, which could dilute owners or restrict its operations.
- Its programs are early, and its business depends on its lead candidate CNTY-813 and its other candidates.
- Its cell therapies use new technology that may be hard to make at scale or fail in trials.
Income statement
Century Therapeutics lost money in fiscal 2025: a net loss of $10 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 223 | 316 | 173 | 189 | 117 |
| Debt incl. finance leases | 10 | 10 | — | — | — |
| Net debt (negative means net cash) | −212 | −305 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | — | — | — |
| Interest coverage | −74.4x | −131.6x | −271.4x | — | — |
| Current ratio | 14.6x | 10.7x | 9.9x | 1.5x | 6.0x |
| Quick ratio | 14.6x | 10.7x | 9.9x | 1.5x | 6.0x |
Cash flow
Projections
Project Century Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $79,511 of Century Therapeutics shares on the open market, and 3 insiders sold $71,284.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Gregory RussottiSee Remarks | Sold | 2,587 | $1.93 | $4,993 | Form 4 |
| Sep 14, 2026 | Douglas CarrSVP Finance & Operations | Sold | 1,658 | $1.93 | $3,200 | Form 4 |
| Sep 8, 2026 | Gregory RussottiSee Remarks | Sold | 534 | $2.05 | $1,095 | Form 4 |
| Sep 8, 2026 | Douglas CarrSVP Finance & Operations | Sold | 254 | $2.05 | $521 | Form 4 |
| Aug 3, 2026 | Douglas CarrSVP Finance & Operations | Sold | 275 | $1.98 | $544 | Form 4 |
| Jun 12, 2026 | Gregory RussottiSee Remarks | Sold | 2,584 | $2.23 | $5,762 | Form 4 |
| Jun 12, 2026 | Douglas CarrSVP Finance & Operations | Sold | 1,654 | $2.23 | $3,688 | Form 4 |
| Jun 8, 2026 | Gregory RussottiSee Remarks | Sold | 524 | $2.11 | $1,106 | Form 4 |
| Jun 8, 2026 | Douglas CarrSVP Finance & Operations | Sold | 249 | $2.11 | $525 | Form 4 |
| May 4, 2026 | Douglas CarrSVP Finance & Operations | Sold | 264 | $2.34 | $618 | Form 4 |
| Mar 12, 2026 | Gregory RussottiSee Remarks | Sold | 10,076 | $2.55 | $25,694 | Form 4 |
| Mar 12, 2026 | Douglas CarrSVP Finance & Operations | Sold | 7,043 | $2.55 | $17,960 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −4,624.5% | −1,479.0% | 1,460.8% |
| Altman Z'' | −4.66 | −7.77 | −6.53 |
| Accruals ratio | −11.4% | −4.6% | 32.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Century Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Century Therapeutics | FY25 | 1,556.8% | −15.8% | −95.9% | — | — | — | |
| ImmunityBio | FY25 | 668.3% | −226.0% | −272.6% | — | — | 3 | Compare |
| Agenus | FY25 | 10.4% | −17.7% | −67.6% | — | — | 3 | Compare |
| Sutro Biopharma | FY25 | 65.2% | −154.5% | — | — | — | 2 | Compare |
| Atara Biotherapeutics | FY25 | −6.3% | 29.7% | −42.2% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | 5 | 2 | 7 | 109 |
| Revenue growth | — | — | — | −57.0% | 194.8% | 1,556.8% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 40 | 76 | 97 | 93 | 107 | 96 |
| Operating income | −54 | −95 | −134 | −146 | −138 | −17 |
| Net income | −54 | −96 | −131 | −137 | −127 | −10 |
| Diluted EPS (US$) | −7.16 | −2.96 | −2.96 | −2.30 | −1.61 | −0.14 |
| Diluted shares (millions) | 8 | 32 | 32 | 59 | 79 | 87 |
| Cash flow | ||||||
| Cash from operations | −41 | −89 | 14 | −88 | −110 | −104 |
| Capital expenditure | 10 | 45 | 31 | 14 | 0 | 1 |
| Free cash flow | −51 | −134 | −17 | −102 | −110 | −105 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 5 | 11 | 15 | 13 | 7 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 76 | 223 | 316 | 173 | 189 | 117 |
| Debt incl. finance leases | 10 | 10 | 10 | — | — | — |
| Total assets | 107 | 437 | 486 | 361 | 353 | 224 |
| Total liabilities | 33 | 41 | 184 | 176 | 192 | 65 |
| Shareholders' equity | −106 | 396 | 303 | 185 | 161 | 159 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | −2,574.2% | −6,556.9% | −2,096.5% | −15.8% |
| Net margin | — | — | −2,518.4% | −6,115.1% | −1,920.9% | −8.8% |
| Free cash flow margin | — | — | −318.4% | −4,567.5% | −1,673.8% | −95.9% |
| Rule of 40 (growth + FCF margin) | — | — | — | −4,624.5% | −1,479.0% | 1,460.8% |
| Return on capital | — | — | −116.6% | — | — | — |
| Return on equity | — | −66.1% | −37.5% | −56.1% | −73.1% | −6.0% |
| Return on assets | — | −35.2% | −28.3% | −32.3% | −35.5% | −3.3% |
| Net debt to EBITDA | — | — | — | — | — | — |